Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 15/20 | 0.46 |
| ▸ | JAK1 | P23458 | 15/20 | 0.46 |
| ▸ | TYK2 | P29597 | 13/20 | 0.46 |
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22349570 | 0.85 | JAK1 (0.52) | CHEK1AURKAJAK2JAK1TYK2 | |
| SCHEMBL21904682 | 0.83 | JAK1 (0.64) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904689 | 0.79 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18538828 | 0.74 | JAK1 (0.70) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904691 | 0.74 | JAK1 (0.71) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904670 | 0.74 | JAK1 (0.62) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904659 | 0.74 | JAK2 (0.66) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904688 | 0.74 | JAK1 (0.60) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22001612 | 0.74 | JAK1 (0.40) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21904706 | 0.73 | JAK2 (0.61) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877389-A1 | CHEMICAL COMPOUNDS | Avista Pharma Solutions, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200138811-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200138811-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138811-A1 | Chemical Compounds | JAK1, JAK3, JAK2 | CHEK1 2493/4885AURKA 330/4885JAK2 3/4885 |
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | CHEK1 2111/4885AURKA 379/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.